Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab
Margherita Rimini,Bernardo Stefanini,Toshifumi Tada,Goki Suda,Shigeo Shimose,Masatoshi Kudo,Fabian Finkelmeier,Changhoon Yoo,José Presa,Elisabeth Amadeo,Virginia genovesi,Maria Caterina De Grandis,Massimo Iavarone,Fabio Marra,Francesco Foschi,Emiliano Tamburini,Federico Rossari,Francesco Vitiello,Linda Bartalini,Caterina Soldà,Francesco Tovoli,Caterina Vivaldi,Sara Lonardi,Marianna Silletta,Takashi Kumada,Naoya Sakamoto,Hideki Iwamoto,Tomoko Aoki,Vera Himmelsbach,Margarida Montes,Atsushi Hiraoka,Takuya Sho,Takashi Niizeki,Naoshi Nishida,Christoph Steup,Masashi Hirooka,Kazuya Kariyama,Joji Tani,Masanori Atsukawa,Koichi Takaguchi,Ei Itobayashi,Shinya Fukunishi,Kunihiko Tsuji,Toru Ishikawa,Kazuto Tajiri,Hironori Ochi,Satoshi Yasuda,Hidenori Toyoda,Chikara Ogawa,Takashi Nishimura,Takeshi Hatanaka,Satoru Kakizaki,Noritomo Shimada,Kazuhito Kawata,Fujimasa Tada,Hideko Ohama,Kazuhiro Nouso,Asahiro Morishita,Akemi Tsutsui,Takuya Nagano,Norio Itokawa,Tomomi Okubo,Taeang Arai,Michitaka Imai,Hisashi Kosaka,Atsushi Naganuma,Yohei Koizumi,Shinichiro Nakamura,Masaki Kaibori,Hiroko Iijima,Yoichi Hiasa,Mara Persano,Silvia Camera,Silvia Foti,Luca Aldrighetti,Stefano Cascinu,Andrea Casadei‐Gardini,Fabio Piscaglia,Maria Caterina De Grandis
DOI: https://doi.org/10.1111/liv.15885
IF: 8.754
2024-03-24
Liver International
Abstract:Introduction Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short‐mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first‐line treatment. Methods and Material The cohort included consecutive patients affected by BCLC‐c and BCLC‐B HCC patients from a multicenter international study group who received atezolizumab plus bevacizumab or lenvatinib as first‐line therapy. Population was stratified according to the BMI in under‐, over‐ and normal‐weight according to the conventional thresholds. The primary objective of the study was to evaluate the prognostic and predictive impact of BMI in patients affected by advanced or intermediate HCC. Survival curves were estimated using the product‐limit method of Kaplan–Meier. The role of stratification factors was analysed with log‐rank tests. Results 1292 consecutive patients with HCC were analysed. 466 (36%) patients were treated with lenvatinib and 826 (64%) patients were treated with atezolizumab plus bevacizumab. In the atezolizumab plus bevacizumab arm, 510 (62%) patients were normal‐weight, 52 (6%) underweight and 264 (32%) overweight. At the univariate analysis for OS, underweight patients had significantly shorter OS compared to normal‐weight patients, whereas no differences were found between normal‐weight versus overweight. Multivariate analysis confirmed that underweight patients had significantly shorter OS compared to normal‐weight patients (HR: 1.7; 95% CI: 1.0–2.8; p = .0323). In the lenvatinib arm, 26 patients (5.6%) were categorized as underweight, 256 (54.9%) as normal‐weight, and 184 (39.5%) as overweight. At the univariate analysis for OS, no significant differences were found between normal‐weight versus underweight and between normal‐weight versus overweight, which was confirmed at multivariate analysis. Conclusion Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib.
gastroenterology & hepatology